biostudies-arrayexpressAlina IsakovaHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-15106We analyzed the U-87 MG cell line, which was treated with temozolomide for 5 days to induce a senescent state. The study aimed to investigate molecular and phenotypic alterations associated with senescence in the context of a malignant phenotype. Senescence was confirmed through β-galactosidase staining (SA-β-gal), assessment of growth arrest, p21 expression and lipofuscin autofluorescence. Due to inconsistency in paired-end read files, only forward (read1) sequences were retained and submitted as single-end data.biostudies-arrayexpressSequencing - RNA sequencing was performed on a HiSeq1500 (Illumina, USA) at Genoanalytika LLC (Russia) Not less than 40 million short reads with a length of 150 nucleotides were generated.Sample Treatment - To induce senescence, the cells were pre-treated with temozolomide (TMZ) (Macklin, China) for at least 5 days. TMZ concentration was pre-selected to be sub-toxic (50 µM).Nucleic Acid Extraction - Total RNA was extracted from cell culture lysates using the Triazol reagent and the PureLink RNA Micro Kit (Invitrogen) according to the protocol provided with the reagent. The quality and quantity of the extracted total RNA were assessed using the BioAnalyzer instrument and the RNA 6000 Nano Kit (Agilent). Subsequently, the total RNA was used to obtain the ribominus fraction using the NEBNext® rRNA Depletion Kit v2 (Human/Mouse/Rat) (NEB, E7400L) following the manufacturer's instructions.Library Construction - Sequencing libraries were prepared from the ribominus RNA fraction using the NEBNext® Ultra™ II RNA Library Prep Kit (E7770S, NEB) according to the manufacturer's protocol. The concentration of the libraries was determined using the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific) on a Qubit 2.0 instrument. The size distribution of the library fragments was assessed using the Agilent High Sensitivity DNA Kit (Agilent). Sequencing was performed on the HiSeq 1500 platform (Illumina), generating at least 40 million short reads with a length of 150 nucleotides each.Growth Protocol - Cell were cultivated in DMEM (PanEco, Russia) supplemented with 10% fetal bovine serum (FBS) (HyClone, USA) at 37°C and 5% CO2, and dissociated by EDTA solution (PanEco, Russia).Sample Collection - Cells were seeded in 25 mm² culture flasks and treated with temozolomide for 5 days. Senescent cells were subsequently cultured for 24 hours without the drug. Control cells were grown in 25 mm² culture flasks and harvested at 80% confluency.OrganizationMINSEQE ScoreAssays and DataProcessed DataMAGE-TAB FilesData Transformation - Raw reads were mapped to the GRCh38 genome using the STAR software (version 2.7.9a), and the number of reads mapped to individual genes (Ensembl annotation, version 99) with no more than three mismatches was counted. Differential gene expression was calculated using the DESeq2 package for R in the RStudio environment . Differential gene expression was performed for non-treated relative to TMZ-treated U87MG cells. Differentially expressed genes (DEGs) were identified based on the significance of gene expression changes using the Wald test adjusted for Benjamin-Hochberg multiple testing (FDR).UnknownTranscriptomicsGenomicsProteomicsIllumina HiSeq 1500RNA-seq of total RNAHomo sapiensAlina IsakovaRoman FadeevMarine GasparianKirill KrasnovAnne YagolovichfalseU-87 MG Temozolomide-Induced Senescence RNA-seq DatasetWe analyzed the U-87 MG cell line, which was treated with temozolomide for 5 days to induce a senescent state. The study aimed to investigate molecular and phenotypic alterations associated with senescence in the context of a malignant phenotype. Senescence was confirmed through β-galactosidase staining (SA-β-gal), assessment of growth arrest, p21 expression and lipofuscin autofluorescence. Due to inconsistency in paired-end read files, only forward (read1) sequences were retained and submitted as single-end data.2025-05-14T00:00:00Z2025-05-01T16:19:03.079Z2025-05-01T16:19:03.079ZE-MTAB-15106ERP172172EFO_0002944EFO_0004170EFO_0009653EFO_0003789EFO_0005518EFO_0003816EFO_0004184EFO_0003969